Jun 18 |
FibroBiologics files for 16.02M shares of common stock by selling shareholder
|
Jun 6 |
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
|
May 15 |
FibroBiologics Announces 2024 Annual Meeting of Stockholders
|
May 15 |
FibroBiologics GAAP EPS of -$0.27
|
May 14 |
FibroBiologics Files 2024 First Quarter Report
|
May 7 |
FibroBiologics to Present at the BIO International Convention 2024
|
Apr 26 |
FibroBiologics files to sell 1.8M units
|
Apr 25 |
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
|
Apr 4 |
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
|
Mar 28 |
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
|